New hope for tough cancers: early trial tests novel drug combo
NCT ID NCT06400160
Summary
This early-stage trial is testing a new drug called TB511, both by itself and in combination with the immunotherapy drug pembrolizumab (Keytruda). It aims to find a safe dose and see if it can shrink tumors in people with advanced solid cancers, including lung, prostate, colorectal, and liver cancer, that have stopped responding to standard treatments. The study will first find the safest dose and then see how well the drug works to control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.